For research use only. Not for therapeutic Use.
GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury[1].
| Catalog Number | I028366 |
| CAS Number | 1268490-12-5 |
| Synonyms | 1-[3,5-dichloro-4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]-3-[3-(trifluoromethyl)phenyl]urea |
| Molecular Formula | C19H14Cl2F3N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H14Cl2F3N5O2/c1-25-15-8-16(27-9-26-15)31-17-13(20)6-12(7-14(17)21)29-18(30)28-11-4-2-3-10(5-11)19(22,23)24/h2-9H,1H3,(H,25,26,27)(H2,28,29,30) |
| InChIKey | QOQADIYOLOHRAW-UHFFFAOYSA-N |
| SMILES | CNC1=CC(=NC=N1)OC2=C(C=C(C=C2Cl)NC(=O)NC3=CC=CC(=C3)C(F)(F)F)Cl |
| Reference | [1]. Patterson JR, et, al. Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf. J Med Chem. 2021 Nov 11;64(21):15651-15670. |
